-1.4‡
-1.6‡
Difference from pioglitazone (adjusted mean † with 95% confidence interval)
-
-
-
-
-
-0.5‡ (-0.7, -0.3)
-0.5‡ (-0.7,-0.3)
-0.6‡ (-0.8,-0.4)
Difference from alogliptin (adjusted mean † with 95% confidence interval)
-
-
-
-
-
-0.4‡ (-0.6, -0.1)
-0.5‡ (-0.7,-0.3)
-0.7‡ (-0.9,-0.5)
Patients (%) achieving A1C ≤7%
6%(8/129)
27%(35/129)
26%(33/129)
30%(38/129)
36%(47/129)
55%(71/130)‡
53%(69/130)‡
60%(78/130)‡
FPG (mg/dL)
N=129
N=126
N=127
N=125
N=129
N=130
N=126
N=127
Baseline (mean)
177
184
177
175
181
179
179
178
Change from baseline (adjusted mean † with 95% confidence interval)
7
-19
-24
-29
-32
-38‡
-42‡
-53‡
Difference from pioglitazone (adjusted mean † with 95% confidence interval)
-
-
-
-
-
-14‡ (-24, -5)
-13‡ (-23, -3)
-20‡ (-30,-11)
Difference from alogliptin (adjusted mean † with 95% confidence interval)
-
-
-
-
-
Intent-to-treat population using last observation carried forward
†Least squares means adjusted for treatment, geographic region, metformin dose and baseline value
‡p≤0.01 when compared to pioglitazone and alogliptin alone
Table 11. Glycemic Parameters at Week 26 for Alogliptin and Pioglitazone Alone and in Combination in Patients with Type 2 Diabetes *
Placebo
Alogliptin 25 mg
Pioglitazone 15 mg
Pioglitazone 30 mg
Pioglitazone 45 mg
Alogliptin 25 mg + Pioglitazone 15 mg
Alogliptin 25 mg + Pioglitazone 30 mg
Alogliptin 25 mg + Pioglitazone 45 mg
A1C (%)
N=126
N=123
N=127
N=123
N=126
N=127
N=124
N=126
Baseline (mean)
8.5
8.6
8.5
8.5
8.5
8.5
8.5
8.6
Change from baseline (adjusted mean † with 95% confidence interval)
-0.1
-0.9
-0.8
-0.9
-1
-1.3‡
-1.4‡
-1.6‡
Difference from pioglitazone (adjusted mean † with 95% confidence interval)
-
-
-
-
-
-0.5‡ (-0.7, -0.3)
-0.5‡ (-0.7,-0.3)
-0.6‡ (-0.8,-0.4)
Difference from alogliptin (adjusted mean † with 95% confidence interval)
-
-
-
-
-
-0.4‡ (-0.6, -0.1)
-0.5‡ (-0.7,-0.3)
-0 |
